Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled and Intravenous D,L-Lysine Acetylsalicylate Glycine in Healthy Adults: A Phase I Study

The primary objective of this study is to evaluate the **pharmacokinetics**, **pharmacodynamics**, and safety of single doses of inhaled and intravenously administered D,L lysine acetylsalicylate • glycine (LASAG) in healthy adult subjects. This investigation is clinically relevant as it aims to determine the optimal dosing and administration route for LASAG, which is intended for the treatment of **migraine**. Understanding these parameters is crucial for ensuring effective and safe therapeutic outcomes in future clinical applications.

The clinical trial involves a **Phase I** study focusing on healthy males and females, with the intended indication being **migraine**. The study population includes both genders, and the age range is categorized under code "3," which typically represents adults. The trial does not specify the total number of participants, as the sponsor has not provided this information. Participants were selected based on their general health status, ensuring they are healthy individuals. The trial population includes a vulnerable population, although specific details regarding lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed key inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the **pharmacokinetics**, **pharmacodynamics**, and safety of single doses of inhaled and intravenously administered D,L lysine acetylsalicylate • glycine (LASAG) in healthy adult subjects. The study is divided into two parts: Part A employs a randomized, cross-over design to compare three dose levels of inhaled LASAG with one dose level of intravenously administered LASAG, while Part B utilizes a single group design to investigate a specific LASAG inhalation solution. The trial is categorized as a Phase I study, with the intended indication being **migraine**. The estimated recruitment start date is May 15, 2023, and the trial is expected to conclude by November 30, 2023.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend multiple follow-up visits to monitor their response to the treatment and collect necessary data. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather comprehensive data for analysis. The expected length of participant involvement will vary depending on the specific part of the study they are enrolled in, but it will generally span the duration of the trial. Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study protocols, or withdrawal of consent by the participant.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The absence of these details suggests that the focus is primarily on the experimental medication, although further clarification would be necessary to confirm this aspect of the trial design.

Due to the lack of specific information, it is not possible to provide additional relevant details about drug administration, dosing schedules, or participant compliance monitoring. The trial documentation does not include any data on the product's authorization status, pharmaceutical form, or the origin of the active substances involved. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be fully articulated based on the current data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 15, 2023, with an estimated completion date of November 30, 2023. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The efficacy parameters will be evaluated at various timepoints throughout the study duration, utilizing appropriate tools and instruments as per the trial protocol. The analysis will be conducted in accordance with the standards of clinical trial methodologies, ensuring the reliability and validity of the results. The trial's primary focus is to determine the efficacy of the intervention under investigation, adhering to the rigorous standards of a Phase 3 clinical trial.